Jun. 17 at 3:34 PM
Analyst raising annual global sales forecasts for obesity treatments to about
$150B by the early 2030s vs top sales ests were in the
$100B range a year ago.
Analysts cite recent data showing the self-injected drugs help stave off costly emergencies like heart attack and stroke or treat chronic conditions like sleep apnea, supporting the case for employers and insurers to pay for them.
Global spending on obesity medications totaled
$24B last year
That +27% annual growth estimate compares with a prior projection of +13%.
Supplies of both
$NVS Wegovy &
$LLY Zepbound remain constrained, but the companies have been increasing production.
In the US 40% of adults are obese & another 30% are overweight. Worldwide adult obesity rate has more than doubled since 1990 - over a billion people globally.
Over 80 experimental obesity drugs have reached the human testing stage but the bull case is that access will widen & higher volume will offset price erosion.
$VKTX $AMGN $HRTS